Pfizer-BioNTech Covid-19 Candidate Shows ‘Positive’ Data; Analyst Sticks To Hold

Pfizer Inc. and BioNTech SE disclosed “positive” data from an early trial of their BNT162b2 mRNA-based vaccine candidate against SARS-CoV2 and confirmed that they were on track to seek regulatory review as early as October.The news drove BioNTech (BNTX) shares up 10% on Friday, while Pfizer rose less than 1% at the close of day.Pfizer (PFE) and BioNTech shared additional Phase 1 safety and immunogenicity data from their ongoing US study of the BNT162 mRNA-based vaccine program against Covid-19.The newly released data shows key safety and immunogenicity data from the US Phase 1 trial for the BNT162b2 vaccine candidate, which …read more

Source:: Yahoo Finance

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.